Abstract
Recombinant preparations of the cytokine interferon (IFN)-α are increasingly used to treat a number of medical conditions, including chronic viral hepatitis and several malignancies. Although frequently effective, IFNαα induces a variety of neuropsychiatric adverse effects, including an acute confusional state that develops rapidly after initiation of high-dose IFNαα, a depressive syndrome that develops more slowly over weeks to months of treatment, and manic conditions most often characterised by extreme irritability and agitation, but also occasionally by euphoria. Acute IFNαα-induced confusional states are typically characterised by disorientation, lethargy, somnolence, psychomotor retardation, difficulties with speaking and writing, parkinsonism and psychotic symptoms. Strategies for managing delirium should be employed, including treatment of contributing medical conditions, use of either typical or atypical antipsychotic agents and avoidance of medications likely to worsen mental status. Significant depressive symptoms occur in 21–58% of patients receiving IFNαα, with symptoms typically manifesting over the first several months of treatment. The most replicated risk factor for developing depression is the presence of mood and anxiety symptoms prior to treatment. Other potential, but less frequently replicated, risk factors include a past history of major depression, being female and increasing IFNα dosage and treatment duration. The available data support two approaches to the pharmacological management of IFNα-induced depression: antidepressant pretreatment or symptomatic treatment once IFNα has been initiated. Pretreatment might be best reserved for patients already receiving antidepressants or for patients who endorse depression or anxiety symptoms of mild or greater severity prior to therapy. Several recent studies demonstrate that antidepressants effectively treat IFNα-induced depression once it has developed, allowing the vast majority of subjects to complete treatment successfully. Recent data suggest that IFNα-induced depression may be composed of two overlapping syndromes: a depression-specific syndrome characterised by mood, anxiety and cognitive complaints, and a neurovegetative syndrome characterised by fatigue, anorexia, pain and psychomotor slowing. Depression-specific symptoms are highly responsive to serotonergic antidepressants, whereas neurovegetative symptoms are significantly less responsive to these agents. These symptoms may be more effectively treated by agents that modulate catecholaminergic functioning, such as combined serotonin-noradrenaline (norepinephrine) antidepressants, bupropion, psychostimulants or modafinil. Additional factors to consider in selecting an antidepressant include potential drug-drug interactions and adverse effect profile. Finally, IFNα appears capable of inducing manic symptoms. Mania, especially when severe, is a clinical emergency. When this occurs, IFNα and antidepressants should be stopped, an emergency psychiatric consultation should be obtained, and treatment with a mood stabiliser should be initiated.
Similar content being viewed by others
Notes
The use of trade names is for product identification purposes only and does not imply endorsement.
References
Schaefer M, Engelbrecht MA, Gut O, et al. Interferon α (IFNa) and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26(4): 731–46
Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon α: a review. Am J Psychiatry 2000; 157(6): 867–76
Trask P, Esper P, Riba M, et al. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J Clin Oncol 2000; 18(11): 2316–26
Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001; 344(13): 961–6
Hauser P, Khosla J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002; 9(7): 942–7
Kraus MR, Schafer A, Faller H, et al. Paroxetine for the treatment of interferon-α-induced depression in chronic hepatitis C. Aliment Pharmacol Ther 2002; 16(6): 1091–9
Renault PF, Hoofnagle JH, Park Y, et al. Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med 1987; 147(9): 1577–80
Meyers CA, Obbens EA, Scheibel RS, et al. Neurotoxicity of intraventricularly administered α-interferon for leptomeningeal disease. Cancer 1991; 68(1): 88–92
Smedley H, Katrak M, Sikora K, et al. Neurological effects of recombinant human interferon. Br Med J (Clin Res Ed) 1983; 286(6361): 262–4
Rohatiner AZ, Prior PF, Burton AC, et al. Central nervous system toxicity of interferon. Br J Cancer 1983; 47(3): 419–22
Niiranen A, Laaksonen R, Iivanainen M, et al. Behavioral assessment of patients treated with α-interferon. Acta Psychiatr Scand 1988; 78(5): 622–6
Mattson K, Niiranen A, Iivanainen M, et al. Neurotoxicity of interferon. Cancer Treat Rep 1983; 67(10): 958–61
Poutiainen E, Hokkanen L, Niemi ML, et al. Reversible cognitive decline during high-dose cc-interferon treatment. Pharmacol Biochem Behav 1994; 47(4): 901–5
Iivanainen M, Laaksonen R, Niemi ML, et al. Memory and psychomotor impairment following high-dose interferon treatment in amyotrophic lateral sclerosis. Acta Neurol Scand 1985; 72(5): 475–80
Farkkila M, Iivanainen M, Roine R, et al. Neurotoxic and other side effects of high-dose interferon in amyotrophic lateral sclerosis. Acta Neurol Scand 1984; 70(1): 42–6
Adams F, Fernandez F, Mavligit G. Interferon-induced organic mental disorders associated with unsuspected pre-existing neurologic abnormalities. J Neurooncol 1988; 6(4): 355–9
Meyers CA, Scheibel RS, Forman AD. Persistent neurotoxicity of systemically administered interferon-α. Neurology 1991; 41(5): 672–6
Schaefer M, Schwaiger M, Pich M, et al. Neurotransmitter changes by interferon-α and therapeutic implications. Pharmacopsychiatry 2003; 36Suppl. 3: S203–6
Blalock JE, Smith EM. Human leukocyte interferon (HuIFNα): potent endorphin-like opioid activity. Biochem Biophys Res Commun 1981; 101(2): 472–8
Valentine AD, Meyers CA, Talpaz M. Treatment of neurotoxic side effects of interferon-a with naltrexone. Cancer Invest 1995; 13(6): 561–6
Licinio J, Kling MA, Hauser P. Cytokines and brain function: relevance to interferon-α-induced mood and cognitive changes. Semin Oncol 1998; 25(1 Suppl. 1): 30–8
Wichers MC, Maes M. The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-α-induced depression. J Psychiatry Neurosci 2004; 29(1): 11–7
Mendoza-Fernandez V, Andrew RD, Barajas-Lopez C. Interferon-α inhibits long-term potentiation and unmasks a longterm depression in the rat hippocampus. Brain Res 2000; 885(1): 14–24
Schwartz TL, Masand PS. The role of atypical antipsychotics in the treatment of delirium. Psychosomatics 2002; 43(3): 171–4
Breitbart W, Marotta R, Platt MM, et al. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 1996; 153(2): 231–7
Hoffman RG, Cohen MA, Alfonso CA, et al. Treatment of interferon-induced psychosis in patients with comorbid hepatitis C and HIV. Psychosomatics 2003; 44(5): 417–20
Mizoi Y, Kaneko H, Oharazawa A, et al. Parkinsonism in a patient receiving interferon a therapy for chronic hepatitis C [in Japanese]. Rinsho Shinkeigaku 1997; 37(1): 54–6
Sarasombath P, Sumida K, Kaku DA. Parkinsonism associated with interferon a therapy for chronic myelogenous leukemia. Hawaii Med J 2002; 61(3): 48, 57
Sunami M, Nishikawa T, Yorogi A, et al. Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-α. Clin Neuropharmacol 2000; 23(1): 59–61
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
Capuron L, Gumnick JF, Musselman DL, et al. Neurobehavioral effects of interferon-α in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002; 26(5): 643–52
Evans DL, Staab JP, Petitto JM, et al. Depression in the medical setting: biopsychological interactions and treatment considerations. J Clin Psychiatry 1999; 60 Suppl. 4: 40–55
Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989; 321(22): 1501–6
Okanoue T, Sakamoto S, Itoh Y, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996; 25(3): 283–91
Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24(4): 778–89
McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339(21): 1485–92
McDonald EM, Mann AH, Thomas HC. Interferons as mediators of psychiatric morbidity: an investigation in a trial of recombinant α-interferon in hepatitis-B carriers. Lancet 1987; II(8569): 1175–8
Lindsay KL, Davis GL, Schiff ER, et al. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy Group. Hepatology 1996; 24(5): 1034–40
Poynard T, Bedossa P, Chevallier M, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med 1995; 332(22): 1457–62
Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339(21): 1493–9
Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358(9286): 958–65
Fried MW, Shiftman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347(13): 975–82
Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003; 37(2): 443–51
Bonaccorso S, Marino V, Biondi M, et al. Depression induced by treatment with interferon-α in patients affected by hepatitis C virus. J Affect Disord 2002; 72(3): 237–41
Miyaoka H, Otsubo T, Kamijima K, et al. Depression from interferon therapy in patients with hepatitis C [letter]. Am J Psychiatry 1999; 156(7): 1120
Kraus MR, Schafer A, Faller H, et al. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry 2003; 64(6): 708–14
Malaguarnera M, Di Fazio I, Restuccia S, et al. Interferon α-induced depression in chronic hepatitis C patients: comparison between different types of interferon a. Neuropsychobiology 1998; 37(2): 93–7
Gohier B, Goeb J, Rannou-Dubas K, et al. Hepatitis C, α interferon, anxiety and depression disorders. World J Biol Psychiatry 2003; 4(3): 115–8
Lang JP, Michel L, Halleguen O. Treatment of affective disorder in hepatitis C: a prospective study in 50 patients. Ann Med Interne (Paris) 2002; 153(7): 22–30
Horikawa N, Yamazaki T, Izumi N, et al. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-α therapy: a prospective study. Gen Hosp Psychiatry 2003; 25(1): 34–8
Pariante CM, Orru MG, Baita A, et al. Treatment with interferon-α in patients with chronic hepatitis and mood or anxiety disorders. Lancet 1999; 354(9173): 131–2
Koskinas J, Merkouraki P, Manesis E, et al. Assessment of depression in patients with chronic hepatitis: effect of interferon treatment. Dig Dis 2002; 20(3–4): 284–8
Dieperink E, Ho SB, Thuras P, et al. A prospective study of neuropsychiatric symptoms associated with interferon-a-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003; 44(2): 104–12
Fontana RJ, Schwartz SM, Gebremariam A, et al. Emotional distress during interferon-α-2B and ribavirin treatment of chronic hepatitis C. Psychosomatics 2002; 43(5): 378–85
Raison CL, Miller AH. The neuroimmunology of stress and depression. Semin Clin Neuropsychiatry 2001; 6(4): 277–94
Cotler SJ, Wartelle CF, Larson AM, et al. Pretreatment symptoms and dosing regimen predict side-effects of interferon therapy for hepatitis C. J Viral Hepat 2000; 7(3): 211–7
Capuron L, Ravaud A. Prediction of the depressive effects of interferon alfa therapy by the patient’s initial affective state [letter]. N Engl J Med 1999; 340(17): 1370
Van Thiel DH, Friedlander L, De Maria N, et al. Treatment of chronic hepatitis C in individuals with pre-existing or confounding neuropsychiatric disease. Hepatogastroenterology 1998; 45(20): 328–30
House JS, Landis KR, Umberson D. Social relationships and health. Science 1988; 241(4865): 540–5
Capuron L, Ravaud A, Miller AH, et al. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-α cancer therapy. Brain Behav Immun 2004 May; 18(3): 205–13
Raison CL, Miller AH. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry 2003; 160: 1554–65
Kent S, Bluthe RM, Kelley KW, et al. Sickness behavior as a new target for drug development. Trends Pharmacol Sci 1992; 13(1): 24–8
Bluthe RM, Dantzer R, Kelley KW. Effects of interleukin-1 receptor antagonist on the behavioral effects of lipopolysaccharide in rat. Brain Res 1992; 573(2): 318–20
Capuron L, Raison CL, Musselman DL, et al. Association of exaggerated HPA axis response to the initial injection of interferon-α with development of depression during interferon-α therapy. Am J Psychiatry 2003; 160(7): 1342–5
Owens MJ, Nemeroff CB. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev 1991; 43(4): 425–73
Penza KM, Heim C, Nemeroff CB. Neurobiological effects of childhood abuse: implications for the pathophysiology of depression and anxiety. Arch Women Ment Health 2003; 6(1): 15–22
Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today 1999; 20(10): 469–73
Moreno FA, Heninger GR, McGahuey CA, et al. Tryptophan depletion and risk of depression relapse: a prospective study of tryptophan depletion as a potential predictor of depressive episodes. Biol Psychiatry 2000; 48(4): 327–9
Capuron L, Neurauter G, Musselman DL, et al. Interferon-α-induced changes in tryptophan metabolism: relationship to depression and paroxetine treatment. Biol Psychiatry 2003 Nov 1; 54(9): 906–14
Capuron L, Ravaud A, Neveu PJ, et al. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 2002; 5(7): 468–73
Bonaccorso S, Marino V, Puzella A, et al. Increased depressive ratings in patients with hepatitis C receiving interferon-α-based immunotherapy are related to interferon-α-induced changes in the serotonergic system. J Clin Psychopharmacol 2002; 22(1): 86–90
Gochee PA, Powell EE, Purdie DM, et al. Association between apolipoprotein E epsilon4 and neuropsychiatrie symptoms during interferon α treatment for chronic hepatitis C. Psychosomatics 2004; 45(1): 49–57
Schaefer M, Schwaiger M, Berg T. Citalopram for the prevention of interferon-α associated depression in psychiatric risk patients. Hepatology 2003; 38(4 Suppl. 1): 320A
Schafer M, Schmidt F, Amann B, et al. Adding low-dose antidepressants to interferon α treatment for chronic hepatitis C improved psychiatric tolerability in a patient with schizoaffective psychosis. Neuropsychobiology 2000; 42Suppl. 1: 43–5
Farah A. Interferon-induced depression treated with citalopram. J Clin Psychiatry 2002; 63(2): 166–7
Gleason OC, Yates WR. Five cases of interferon-α-induced depression treated with antidepressant therapy. Psychosomatics 1999; 40(6): 510–2
Gleason OC, Yates WR, Isbell MD, et al. An open-label trial of citalopram for major depression in patients with hepatitis C. J Clin Psychiatry 2002; 63(3): 194–8
Levenson JL, Fallon HJ. Fluoxetine treatment of depression caused by interferon-α. Am J Gastroenterol 1993; 88(5): 760–1
Schramm TM, Lawford BR, MacDonald GA, et al. Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Aust 2000; 173(7): 359–61
Yoshida K, Higuchi H, Takahashi H, et al. Favorable effect of milnacipran on depression induced by interferon-α. J Neuropsychiatry Clin Neurosci 2003; 15(2): 242–3
Janssen HL, Brouwer JT, Van Der Mast RC, et al. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol 1994; 21(2): 241–3
Weiss K. Safety profile of interferon-α therapy. Semin Oncol 1998; 25(1 Suppl. 1): 9–13
Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997; 32Suppl. 1: 1–21
Demetrashvili MD, Miller AH, Raison CL. Managing psychiatric side effects of interferon. Proceedings of the 1st Annual Clinical Care Options for Hepatitis Symposium; 2003 Jun 19–22; Laguna Niguel (CA) [online]. Available from URL: http://clinicaloptions.com/hep [Accessed 2004 Nov 15]
Owen JR, Nemeroff CB. New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine. Depress Anxiety 1998; 7 Suppl. 1: 24–32
Gleason OC, Yates WR, Philipsen MA, et al. Plasma levels of citalopram in depressed patients with hepatitis C. Psychosomatics 2004; 45(1): 29–33
Thase ME. Effects of venlafaxine on blood pressure: a metaanalysis of original data from 3744 depressed patients. J Clin Psychiatry 1998; 10(59): 502–8
Ahmed F, Rovner D, Jacobson IM, et al. Seizures during pegylated interferon and ribavirin therapy for chronic hepatitis C in the WIN-R trial [abstract]. Hepatology 2003; 38(4 Suppl. 1): 734A
Weinrieb R, Auriacombe M, Lynch KG, et al. A critical review of selective serotonin reuptake inhibitor-associated bleeding: balancing the risk of treating hepatitis C-infected patients. J Clin Psychiatry 2003; 64: 1502–10
Edwards IR. Withdrawing drugs: nefazodone, the start of the latest saga. Lancet 2003; 361(9365): 1240
Park-Wyllie LY, Antoniou T. Concurrent use of bupropion with CYP2B6 inhibitors, nelfinavir, ritonavir and efavirenz: a case series. AIDS 2003; 17(4): 638–40
Nelson JC, Mazure CM, Bowers Jr MB, et al. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991; 48(4): 303–7
Debatista C, Solvason HB, Poirier J, et al. A prospective trial of bupropion SR augmentation in partial and non-responders to serotonergic antidepressants. J Psychopharmacol 2003; 23(1): 27–30
Tran PV, Bymaster FP, Mcnamara RK, et al. Dual monoamine modulation for improved treatment of major depressive disorder. J Clin Psychopharmacol 2003; 23(1): 78–86
Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992; 326(19): 1250–6
Goodnick PJ. Treatment of chronic fatigue syndrome with venlafaxine [letter]. Am J Psychiatry 1996; 153(2): 294
Goodnick PJ. Bupropion in chronic fatigue syndrome [letter]. Am J Psychiatry 1990; 147(8): 1091
Goodnick PJ, Sandoval R, Brickman A, et al. Bupropion treatment of fluoxetine-resistant chronic fatigue syndrome. Biol Psychiatry 1992; 32(9): 834–8
Schwartz AL, Thompson JA, Masood N. Interferon-induced fatigue in patients with melanoma: a pilot study of exercise and methylphenidate. Oncol Nurs Forum Online 2002; 29(7): E85–90
Sugawara Y, Akechi T, Shima Y, et al. Efficacy of methylphenidate for fatigue in advanced cancer patients: a preliminary study. Palliat Med 2002; 16(3): 261–3
Sarhill N, Walsh D, Nelson KA, et al. Methylphenidate for fatigue in advanced cancer: a prospective open-label pilot study. Am J Hosp Palliat Care 2001; 18(3): 187–92
Zifko UA, Rupp M, Schwarz S, et al. Modafinil in treatment of fatigue in multiple sclerosis: results of an open-label study. J Neurol 2002; 249(8): 983–7
Afdhal NH, Klopfer A, Tang L, et al. Hemoglobin increase is independently associated with increased health-related quality of life (HRQL) in anemic interferon/ribavirin (IFN/RBV)-treated hepatitis C virus (HCV)-infected patients treated with epoetin alfa. Hepatology 2003; 38(4 Suppl. 1): 312A
Afdhal NH, Goon B, Smith K, et al. Epoetin alfa (EPO) improves and maintains health-related quality of life (HRQL) in anemic HCV-infected patients receiving interferon/ribavirin (IFN/RBV): HRQL results from the proactive study. Hepatology 2003; 38(4 Suppl. 1): 302A
Altindag A, Ozbulut O, Ozen S, et al. Interferon-α-induced mood disorder with manic features. Gen Hosp Psychiatry 2001; 23(3): 168–70
Carpiniello B, Orru MG, Baita A, et al. Mania induced by withdrawal of treatment with interferon alfa. Arch Gen Psychiatry 1998; 55(1): 88–9
Kanno A, Yamada M, Abe M, et al. A case of interferon α induced manic psychosis in chronic hepatitis C. Tohoku J Exp Med 1999; 187(1): 79–82
Monji A, Yoshida I, Tashiro K, et al. A case of persistent manic depressive illness induced by interferon-alfa in the treatment of chronic hepatitis C. Psychosomatics 1998; 39(6): 562–4
Strite D, Valentine AD, Meyers CA. Manic episodes in two patients treated with interferon α. J Neuropsychiatry Clin Neurosci 1997; 9(2): 273–6
Onyike CU, Bonner JO, Lyketsos CG, et al. Mania during treatment of chronic hepatitis C with pegylated interferon and ribavirin. Am J Psychiatry 2004; 61(3): 429–35
Castera L, Constant A, Henry C, et al. Incidence, risk factors and treatment of mood disorders associated with peginterferon and ribavirin therapy in patients with chronic hepatitis C: results of a prospective study [abstract]. Hepatology 2003; 38(4 Suppl. 1): 735A
Gould RA, Ball S, Kaspi SP, et al. Prevalence and correlates of anger attacks: a two site study. J Affect Disord 1996; 39(1): 31–8
Appels A. Why do imminent victims of a cardiac event feel so tired? Int J Clin Pract 1997; 51(7): 447–50
Altshuler LL, Post RM, Leverich GS, et al. Antidepressantinduced mania and cycle acceleration: a controversy revisited. Am J Psychiatry 1995; 152(8): 1130–8
Acknowledgements
The authors would like to thank Bobbi J. Woolwine for her support in the preparation of this article. This work was supported in part by the National Institute of Mental Health (MH64619, MH069124 and MH60723) and the Centers for Disease Control and Prevention. Potential conflicts of interest: Charles L. Raison, MD, Speakers’ Bureau for Schering Plough, Wyeth and Eli Lilly; Marina Demetrashvili, no relationships to disclose; Lucile Capuron, no relationships to disclose; Andrew H. Miller, no relationships to disclose.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Raison, C.L., Demetrashvili, M., Capuron, L. et al. Neuropsychiatric Adverse Effects of Interferon-α. CNS Drugs 19, 105–123 (2005). https://doi.org/10.2165/00023210-200519020-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00023210-200519020-00002